If Zytiga eventually gets approved for non-metastatic prostate cancer, it could conceivably reduce the number of da Vinci procedures by shrinking localized tumors to the point where less invasive procedures were sufficient. However, this seems like a second-order matter, at most, for ISRG.
Market Data 
Markets 
AI
